LPCN
Lipocine Inc.
Key Financials
Net Income
$-9627505
↓ 115371.9%
Operating Income
$-10371379
↓ 797.9%
Revenue
$2.0M
↓ 82.3%
EPS (Diluted)
$-1.69
↑ 46.2%
Total Liabilities
$2.5M
↑ 67.1%
Shareholders' Equity
$14.5M
↓ 31.1%
Cash & Equivalents
$5.2M
↓ 16.1%
Total Assets
$17.0M
↓ 24.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 4 | 8/7/2026 | View on SEC |
| 3 | 8/7/2026 | View on SEC |
| 8-K | 8/4/2026 | View on SEC |
| 10-Q | 8/4/2026 | View on SEC |
| 8-K | 8/3/2026 | View on SEC |
| 4 | 6/30/2026 | View on SEC |
| 8-K | 6/12/2026 | View on SEC |
| S-8 | 6/9/2026 | View on SEC |
| 8-K | 6/4/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | LPCN |
| Company Name | Lipocine Inc. |
| CIK | 1535955 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 801 994 7383 |